HTK Solution Cardioplegia in Pediatric Patients: A Meta-analysis

Abstract

Introduction Cardioplegia, a therapy designed to induce reversible cardiac arrest, revolutionized cardiovascular surgery. Among the various pharmacological approaches is the histidine-tryptophan-ketoglutarate (HTK) solution. Despite numerous studies, no meta-analysis has investigated the efficacy of the HTK solution in the pediatric population. Therefore, we aim to conduct a meta-analysis comparing HTK and other cardioplegia solutions in pediatric patients undergoing cardiovascular surgery.

Methods PubMed, Embase, and Cochrane databases were searched from inception through April 2024. Endpoints were computed in odds ratios (OR) with 95% confidence intervals (CI) for dichotomous variables, whereas continuous variables were compared using mean differences (MD) with 95% CI.

Results A total of 11 studies comprising 1,349 patients were included, of whom 677 (50.19%) received HTK cardioplegia. The results were similar between groups regarding mortality (OR 0.98; 95% CI 0.29, 3.29), length of hospital stay (MD 0.32 days; 95% CI −0.88, 1.51), Mechanical ventilation (MV) (MD −17.72 hours; 95% CI −51.29, 15.85), arrhythmias (OR 1.27; 95% CI 0.83, 1.95), and delayed sternal closure (OR 0.89; 95% 0.56, 1.43). However, transfusion volume was lower in the HTK group (MD −452.39; 95% CI −890.24, −14.53; p = 0.04).

Conclusion The use of HTK solution was demonstrated to be similar regarding its clinical efficacy to other approaches for cardioplegia, and it may present advantages to patients prone to hypervolemia.

Keywords

cardiac surgery - cardioplegia - Custodiol solution - HTK solution - pediatric

Data Availability Statement

The data associated with the paper are available in PubMed, Cochrane, and Embase.

Authors' Contribution

All authors read and approved the final version of the manuscript.

Publication History

Received: 08 July 2024

Accepted: 31 October 2024

Accepted Manuscript online:
05 November 2024

Article published online:
29 November 2024

• References

• 1 Huang JB, Liang J, Zhou LY. Eisenmenger syndrome: not always inoperable. Respir Care 2012; 57 (09) 1488-1495
• 2 Lin YZ, Huang JB, Li XW. et al. Clinical comparative analysis of histidine-tryptophan-ketoglutarate solution and St. Thomas crystalloid cardioplegia: a 12-year study from a single institution. Exp Ther Med 2017; 14 (03) 2677-2682
• 3 Bojan M, Peperstraete H, Lilot M, Tourneur L, Vouhé P, Pouard P. Cold histidine-tryptophan-ketoglutarate solution and repeated oxygenated warm blood cardioplegia in neonates with arterial switch operation. Ann Thorac Surg 2013; 95 (04) 1390-1396
• 4 Carvajal C, Goyal A, Tadi P. Cardioplegia. StatPearls Publishing; 2022 . Accessed at: https://pubmed.ncbi.nlm.nih.gov/32119350/#:~:text=Cardioplegia%20is%20a%20pharmacological%20therapy
• 5 Qulisy EA, Fakiha A, Debis RS, Jamjoom AA, Elassal AA, Al-Radi OO. Custodiol versus blood cardioplegia in pediatric cardiac surgery, two-center study. J Egyptian Soc Cardiothorac Surg 2016; 24 (01) 38-42
• 6 Albadrani M. Histidine-tryptophan-ketoglutarate solution versus multidose cardioplegia for myocardial protection in cardiac surgeries: a systematic review and meta-analysis. J Cardiothorac Surg 2022; 17 (01) 133
• 7 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372 (71) n71
• 8 Sterne JAC, Savović J, Page MJ. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898
• 9 Sterne JAC, Hernán MA, Reeves BC. et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919
• 10 McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 2021; 12 (01) 55-61
• 11 Mercuri M, Gafni A. The evolution of GRADE (part 3): a framework built on science or faith?. J Eval Clin Pract 2018; 24 (05) 1223-1231
• 12 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414) 557-560
• 13 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (03) 177-188
• 14 Valente AS, Lustosa GP, Mota LAM. et al. Comparative analysis of myocardial protection with HTK solution and hypothermic hyperkalemic blood solution in the correction of acyanogenic congenital cardiopathies—a randomized study. Braz J Cardiovasc Surg 2019; 34 (03) 271-278
• 15 Bibevski S, Mendoza L, Ruzmetov M. et al. Custodiol cardioplegia solution compared to cold blood cardioplegia in pediatric cardiac surgery: a single-institution experience. Perfusion 2020; 35 (04) 316-322
• 16 Elmahrouk AF, Shihata MS, Al-Radi OO. et al. Custodiol versus blood cardioplegia in pediatric cardiac surgery: a randomized controlled trial. Eur J Med Res 2023; 28 (01) 404
• 17 Giordano R, Arcieri L, Cantinotti M. et al. Custodiol solution and cold blood cardioplegia in arterial switch operation: retrospective analysis in a single center. Thorac Cardiovasc Surg 2016; 64 (01) 53-58
• 18 Li XW, Lin YZ, Lin H. et al. Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution. Braz J Med Biol Res 2016; 49 (06) e5208
• 19 Liu J, Feng Z, Zhao J, Li B, Long C. The myocardial protection of HTK cardioplegic solution on the long-term ischemic period in pediatric heart surgery. ASAIO J 2008; 54 (05) 470-473
• 20 Talwar S, Chatterjee S, Sreenivas V. et al. Comparison of del Nido and histidine-tryptophan-ketoglutarate cardioplegia solutions in pediatric patients undergoing open heart surgery: a prospective randomized clinical trial. J Thorac Cardiovasc Surg 2019; 157 (03) 1182-1192.e1
• 21 Wang ZH, An Y, Du MC. et al. Clinical assessment of histidine-tryptophan-ketoglutarate solution and modified St. Thomas' solution in pediatric cardiac surgery of tetralogy of Fallot. Artif Organs 2017; 41 (05) 470-475